170 related articles for article (PubMed ID: 33206282)
1. SB8: A Bevacizumab Biosimilar.
Syed YY
Target Oncol; 2020 Dec; 15(6):787-790. PubMed ID: 33206282
[TBL] [Abstract][Full Text] [Related]
2. A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer.
Reck M; Luft A; Bondarenko I; Shevnia S; Trukhin D; Kovalenko NV; Vacharadze K; Andrea F; Hontsa A; Choi J; Shin D
Lung Cancer; 2020 Aug; 146():12-18. PubMed ID: 32502923
[TBL] [Abstract][Full Text] [Related]
3. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
4. FKB238: A Bevacizumab Biosimilar.
Syed YY
Clin Drug Investig; 2021 Sep; 41(9):825-828. PubMed ID: 34347284
[TBL] [Abstract][Full Text] [Related]
5. A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers.
Shin D; Lee YJ; Choi J; Lee D; Park M; Petkova M
Cancer Chemother Pharmacol; 2020 Oct; 86(4):567-575. PubMed ID: 32949267
[TBL] [Abstract][Full Text] [Related]
6. MYL-1402O: A Bevacizumab Biosimilar.
Lee A
Target Oncol; 2022 Jan; 17(1):85-88. PubMed ID: 34910269
[TBL] [Abstract][Full Text] [Related]
7. FKB327: An Adalimumab Biosimilar.
Al-Salama ZT
BioDrugs; 2019 Feb; 33(1):113-116. PubMed ID: 30712241
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
9. GP2017: An Adalimumab Biosimilar.
Heo YA
BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D; Kim J; Yun J; Park SJ
Adv Ther; 2020 Oct; 37(10):4308-4324. PubMed ID: 32816233
[TBL] [Abstract][Full Text] [Related]
12. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin
Li CSW; Sweeney K; Cronenberger C
Cancer Chemother Pharmacol; 2020 Mar; 85(3):487-499. PubMed ID: 31768697
[TBL] [Abstract][Full Text] [Related]
14. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
15. Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab.
Cao D; Deng C; Wang G; Mei X; Xie J; Liu Y; Liu Y; Yang Y; Li S; Liu C
Drugs R D; 2023 Sep; 23(3):267-288. PubMed ID: 37479945
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer: A Phase III, Randomized, Double-blind, Noninferiority Clinical Trial.
Rezvani H; Mortazavizadeh SM; Allahyari A; Nekuee A; Najafi SN; Vahidfar M; Ghadyani M; Khosravi A; Qarib S; Sadeghi A; Esfandbod M; Rajaeinejad M; Rezvani A; Hajiqolami A; Payandeh M; Shazad B; Anjidani N; Meskinimood S; Alikhasi A; Karbalaeian M; Salari S
Clin Ther; 2020 May; 42(5):848-859. PubMed ID: 32334845
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males.
Cho SH; Han S; Ghim JL; Nam MS; Yu S; Park T; Kim S; Bae J; Shin JG
BioDrugs; 2019 Apr; 33(2):173-181. PubMed ID: 30850957
[TBL] [Abstract][Full Text] [Related]
18. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
19. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
20. A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab.
Hummel M; Bosje T; Shaw A; Liu MS; Barve A; Kothekar M; Socinski MA; Waller CF
J Cancer Res Clin Oncol; 2022 Feb; 148(2):487-496. PubMed ID: 33866430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]